Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MeiraGTx Holdings plc - Ordinary Shares
(NQ:
MGTX
)
7.375
+0.095 (+1.30%)
Streaming Delayed Price
Updated: 3:18 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MeiraGTx Holdings plc - Ordinary Shares
< Previous
1
2
3
4
Next >
The Biotech Tug-of-War: Is Kiora Pharmaceuticals Positioned to Ride the 2025 Commodity Wave?
December 18, 2025
As of December 18, 2025, the financial landscape is defined by a stark divergence in the commodities market, creating a complex environment for clinical-stage biotechnology firms. While gold prices...
Via
MarketMinute
Topics
Derivatives
Economy
Intellectual Property
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
November 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle?
↗
November 10, 2025
Via
Stocktwits
Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration
↗
November 10, 2025
MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children with LCA4.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
November 10, 2025
Via
Benzinga
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
November 10, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
October 07, 2025
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Sales Jump 1,133 Percent
↗
August 14, 2025
Via
The Motley Fool
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
August 14, 2025
From
MeiraGTx
Via
GlobeNewswire
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
↗
May 14, 2025
Via
Benzinga
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
May 13, 2025
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
May 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
May 09, 2025
From
MeiraGTx
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
March 13, 2025
Via
Benzinga
There are notable gap-ups and gap-downs in today's session.
↗
March 13, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.
Via
Chartmill
Crude Oil Falls 1%; Dollar General Posts Upbeat Sales
↗
March 13, 2025
Via
Benzinga
G-III Apparel Posts Better-Than-Expected Earnings, Joins Ballard Power Systems, Dollar General And Other Big Stocks Moving Higher On Thursday
↗
March 13, 2025
Via
Benzinga
MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars
↗
March 13, 2025
MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.
Via
Benzinga
Topics
Artificial Intelligence
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
March 13, 2025
Via
Benzinga
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
March 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process
March 13, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
February 21, 2025
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
January 22, 2025
MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company’s proprietary...
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
December 09, 2024
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
November 13, 2024
From
MeiraGTx
Via
GlobeNewswire
Jim Cramer: This Tech Stock Is A Buy, SoFi Technologies Is Good
↗
November 08, 2024
SoFi Technologies, Inc. is good, Jim Cramer said. It reported third-quarter adjusted sales of $689.445 million, according to Benzinga Pro.
Via
Benzinga
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
October 22, 2024
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms
From
MeiraGTx
Via
GlobeNewswire
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
↗
October 15, 2024
Via
Benzinga
Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints
↗
October 15, 2024
MeiraGTx's clinical study of AAV-GAD for Parkinson's disease showed significant improvements in motor function and quality of life in high- and low-dose groups, with no serious adverse events....
Via
Benzinga
Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views
↗
October 15, 2024
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
